The University of Utah spinout is looking to float on the Nasdaq Global Select Market and has filed with a $100m placeholder amount.

Recursion Pharmaceuticals, a US-based drug discovery technology spinout of University of Utah, has filed to raise $100m in an initial public offering that would allow pharmaceutical and chemicals group Bayer to exit. Founded in 2013, Recursion uses machine learning technology to research and develop drug treatments for health conditions such as cancer, neurological diseases and…

The rest of this content is only accessible to University Venturing: News, Data and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.